Trying to estimate market cap based on what is actually known, but even a generous UK only model does not get me to much greater than current valuations.
Start with NWBO’s own leukapheresis clinic. The PR says about 4 patients per day, with flexibility for extended hours and weekend operations. Even if I generously assume 7-day operation, that is only:
4 × 7 × 52 = 1,456 patients per year
So using roughly 3,000 new UK GBM cases per year already assumes NWBO eventually expands beyond the announced clinic capacity and can somehow treat all new UK GBM cases.
NWBO previously referenced a potential DCVax price of about $37,000/year, but that figure is roughly 15 years old. Inflation adjusted to 2026, a rough current equivalent would be around $55,000 to $65,000/year, depending on the inflation assumption. NICE negotiations could also push the actual reimbursed price lower.
Then account for attrition. If median OS is around 18 to 19 months, a rough model of:
Year 1: 100%
Year 2: 50%
Year 3: 20%
gives about 1.7 billable patient-years per starting patient.
After roughly three years of operation, once the treatment pipeline is filled, that gives:
3,000 × 1.7 = about 5,100 billable patient-years per year
At different pricing assumptions, that implies:
$37,000/year = about $189 million annual steady-state revenue
$55,000/year = about $281 million annual steady-state revenue
$65,000/year = about $332 million annual steady-state revenue
At a 10% EBITDA margin, that becomes:
$19 million EBITDA at $37,000/year
$28 million EBITDA at $55,000/year
$33 million EBITDA at $65,000/year
Using a 10x EBITDA multiple, which seems reasonable for a UK only, early commercial, capacity constrained personalized therapy model, that gives roughly:
$190 million market cap at $37,000/year
$280 million market cap at $55,000/year
$330 million market cap at $65,000/year
With roughly 1.6 billion shares, that implies about:
$0.12/share at $37,000/year
$0.18/share at $55,000/year
$0.21/share at $65,000/year
So even using all new UK GBM cases and a 2026 adjusted price range, the grounded UK only model still does not get to multi dollar valuations.
To be clear, that does not mean the stock cannot spike on MHRA approval. Even after approval, the stock could continue to trade on a bundle of speculations, including EDEN, FDA approval, broader geography, higher pricing, higher margins, additional indications, a partnership, or a buyout. But those are separate assumptions.
Market Data 
Markets 
